Data from Exact Sciences showed its DNA-based Cologuard test had 92% sensitivity for colorectal cancer, but only 42% sensitivity for finding precancerous polyps. The Agency for Healthcare Research and Quality last year found that there was insufficient evidence to support the use of tests such as Cologaurd in cancer screening.

Related Summaries